Gene

TP53

tumor protein p53

Explore in graph →CI-GENE-00035913HGNC:11998 ENSG00000141510 NCBI 7157 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (408)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 401–408 of 408 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 Y220C3
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022) msk_spectrum_tme_2022	unmapped	Ssm	81	82

Literature

Linked publications (58)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 58 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411 · validated

TP53 Y220H2
(functional)	—UNRESOLVED	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10239 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Does Not Support Dominant Negative	3	submitted	EID10572 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant Y220H originally identified in CNS lymphoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivat… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic

TP53 Y220H2

(functional)

—UNRESOLVED

Functional

Does Not Support Dominant Negative

accepted

EID10239

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic

〃

—UNRESOLVED

Functional

Does Not Support Dominant Negative

submitted

EID10572

Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant Y220H originally identified in CNS lymphoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivat… (full text at CIViC)

PMID 10519380 · Marutani et al., 1999 · Open in CIViC

civic

TP53 Y234C1
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	C	Supports Resistance	—	accepted	EID2745 Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic

TP53 Y234C1

Carboplatin + CisplatinSubstitutes

Malignant Ovarian Neoplasm

Predictive

Supports Resistance

—

accepted

EID2745

Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

civic

TP53 Y234H1
(functional)	—UNRESOLVED	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10241 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic

TP53 Y234H1

(functional)

—UNRESOLVED

Functional

Does Not Support Dominant Negative

accepted

EID10241

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic

TP53 Y236S1
(functional)	—UNRESOLVED	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10226 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic

TP53 Y236S1

(functional)

—UNRESOLVED

Functional

Does Not Support Dominant Negative

accepted

EID10226

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic